AIPAC - "Spotlight poster". Sat 12 December 7.15am AEST (Ahjay - have a sleep-in before daily report!!).
PD14-08 Primary efficacy results from AIPAC: A double-blinded, placebo controlled, randomized multinational phase IIb trial comparing weekly paclitaxel plus eftilagimod alpha (soluble LAG-3 protein) vs. weekly paclitaxel plus placebo in HR-positive metastatic breast cancer patients.
Wildiers H, Armstrong A, Cuypere E, Dalenc F, Dirix L, Chan S, Marme F, Schröder CP, Huober J, Wagemans J, Vuylsteke P, Jacquin J-P, Brain E, Kümmel S, Pápai Z, Perjesi L, Mueller C, Brignone C, Triebel F.
Department of General Medical Oncology and Multidisciplinary Breast Centre, Leuven, Belgium;
The Christie NHS Foundation Trust, Manchester, United Kingdom; AZ Sint-Jan Burgge-Oostende AV, Ruddershove, Belgium;
Institut Claudius Regaud, Toulouse, France; GZA ziekenhuizen campus Sint-Augustinus, Oosterveldlaan, Belgium;
Nottingham Cancer Clinical Trials Team (NCCTT), Nottingham, United Kingdom;
National Center for Tumor Diseases (NCT) Heidelberg, Heidelberg, Germany;
University Medical Center Groningen, Groningen, Netherlands;
Universitätsfrauenklinik Ulm, Ulm, Germany; AZ Sint-Maarten, Mechelen, Belgium;
CHU UCL Namur, St Elisabeth, Belgium;
Institut de Cancérologie de la Loire (ICO) Lucien Neuwirth, Saint Priest en Jarez, France;
Institut Curie - Hôpital René Huguenin, Saint-Cloud, France;
KEM | Evang. Kliniken Essen-Mitte, Essen, Germany;
MH Egészségügyi Központ Onkológiai Osztály, Budapest, Hungary;
Immutep, Budapest, Hungary; Clinical Development,
Immutep, Berlin, Germany; Research & Development, Immutep, Paris, France.
- Forums
- ASX - By Stock
- LAG-3
AIPAC - "Spotlight poster". Sat 12 December 7.15am AEST (Ahjay -...
-
- There are more pages in this discussion • 40 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add IMM (ASX) to my watchlist
(20min delay)
|
|||||
Last
31.5¢ |
Change
-0.005(1.56%) |
Mkt cap ! $458.1M |
Open | High | Low | Value | Volume |
32.0¢ | 32.8¢ | 31.0¢ | $1.817M | 5.763M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
3 | 71665 | 31.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
32.0¢ | 36363 | 2 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
3 | 71665 | 0.310 |
17 | 336339 | 0.305 |
21 | 385559 | 0.300 |
4 | 79250 | 0.295 |
8 | 215108 | 0.290 |
Price($) | Vol. | No. |
---|---|---|
0.320 | 36363 | 2 |
0.325 | 297337 | 6 |
0.330 | 97094 | 5 |
0.335 | 164962 | 3 |
0.340 | 110101 | 4 |
Last trade - 16.10pm 15/10/2024 (20 minute delay) ? |
Featured News
IMM (ASX) Chart |
The Watchlist
JBY
JAMES BAY MINERALS LIMITED
Andrew Dornan, Executive Director
Andrew Dornan
Executive Director
SPONSORED BY The Market Online